## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.35 indicates fundamental undervaluation. Quality metrics strong (ROE 18%). Caution: momentum weakening (-1.6% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($306.72)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. UnitedHealth Axes Reimbursement Suit on ERISA Preemption Grounds**
- Source: Bloomberg Law News | 20251202T230600 | Bullish | Relevance: 99%
- UnitedHealth Group Inc. successfully defended an insurance reimbursement lawsuit after a federal appeals court affirmed the Employee Retirement Income Security Act's (ERISA) broad preemptive power over state claims. The Sixth Circuit Court of Appeals ruled that state law claims brought by a plan participant seeking ERISA plan benefits are subject to complete preemption under ERISA. This decision affirmed the dismissal of an Ohio state law claim against UnitedHealth brought by a participant injured in a car accident.

**2. Is UnitedHealth an Undervalued Stock to Buy Now?**
- Source: Finviz | 20251202T063800 | Somewhat-Bullish | Relevance: 99%
- UnitedHealth Group faces challenges including rising costs, a volatile political landscape regarding ACA subsidies, and scrutiny over its business practices. The company plans to raise premiums and shed unprofitable business to improve margins, anticipating a decrease in enrollment but aiming for long-term annualized earnings growth of 13% to 16%. Despite potential political threats to the healthcare industry, the stock is considered undervalued with a compelling price-to-earnings ratio, offering significant upside potential.

**3. UnitedHealth to exit Latin America with $1B Banmedica sale - Reuters (UNH:NYSE)**
- Source: Seeking Alpha | 20251201T043700 | Neutral | Relevance: 99%
- UnitedHealth Group (UNH) has reportedly agreed to sell its remaining South American unit, Banmedica, to Brazilian private equity firm Patria Investments (PAX) for approximately $1 billion. This sale signifies UnitedHealth's exit from the Latin American market. The deal, cited by Reuters based on familiar sources, has already been signed.

**4. Is UnitedHealth's Valuation Dip & Divestment Diet a Real Buy Window?**
- Source: TradingView | 20251202T190601 | Neutral | Relevance: 98%
- UnitedHealth Group (UNH) appears reasonably valued despite a recent valuation dip and strategic divestments, trading below its five-year median P/E but above the industry average. While the company faces near-term challenges from rising medical costs, regulatory scrutiny, and fluctuating membership, its strong market position, diversified model, and long-term demand drivers for healthcare services maintain its investment case. Management anticipates a rebound in earnings growth by 2026, supported by repricing efforts and operational efficiency initiatives.

**5. UnitedHealth Group (UNH) Stock Today: Price, Forecast and 2026 Recovery Prospects (December 2, 2025)**
- Source: ts2.tech | 20251202T160454 | Somewhat-Bullish | Relevance: 98%
- UnitedHealth Group (UNH) stock is trading around $325-326 on December 2, 2025, significantly below its 52-week high but with Wall Street maintaining a "Buy" consensus and double-digit upside potential for 2026. The article discusses a turbulent 2025 for UNH, marked by an earnings miss, regulatory scrutiny, a cyberattack, and strategic shifts like exiting Latin America, while also highlighting a Q3 beat and revised 2025 EPS guidance, positioning UNH as a high-risk, high-reward turnaround story for investors. Despite ongoing regulatory, reputational, and medical cost risks, analysts see UNH as potentially undervalued, with a long-term earnings growth target of 13-16% and a 2.7% dividend yield, making it a "battleground stock" for risk-tolerant investors.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 23 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Long-term trend broken: trading 11.0% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.35 suggests fair value with growth premium. Forward P/E 18.3x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $297.5B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.35 |
| Forward P/E | 18.3 |
| Current P/E | 19.9 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.1% to -1.4% (-1.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >4.0% for momentum thesis). Below SMA200 (0.89x), long-term trend not supportive. MACD histogram positive (1.40), confirming momentum. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.45% (CS: 41) | Neutral |
| RSI_14 | 45.6 | Neutral |
| MACD Histogram | 1.40 | Bullish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 0.946x | Below |
| vs SMA200 | 0.890x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $324.54
- **Stop Loss:** $306.72 (5.5% risk)
- **Target:** $360.18 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 56
- **Position Value:** $18,174.24
- **Portfolio %:** 18.17%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*